Mankind Pharma Q1 FY27 PAT up 34% standalone, 29% consolidated

Pat Growth 25pctEmphasis Of MatterResults RestatedRelated Party TransactionsResults View source PDF Explain this filing

MANKIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.8%Reaction day

₹2590.10

prior close

₹2584.90

announcement price

In-mkt

timing

Nifty Midcap 150market-0.4%-0.4% vs market

Pharmaceuticals peers, median of 162sector-0.7%-0.1% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty Midcap 150 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.8-0.4-0.4-0.7-0.1

Next day

-4.6+0.1-4.6-0.5-4.1

-4.1+1.3-5.4+0.2-4.3

-5.2+1.0-6.2+0.1-5.3

-5.8+1.2-7.0+0.5-6.3

-6.6+0.8-7.4+0.7-7.3

-5.9+1.5-7.4+1.4-7.3

15d

-7.9+1.1-9.1+0.4-8.3

-6.6+1.8-8.4+1.7-8.3

-3.3-5.4+2.1+3.0-6.4

-3.8pendingpending-2.4-1.4

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 162Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Q1 FY27 standalone revenue rose 15% YoY to Rs 2,964 cr, PAT up 34.5% to Rs 558 cr. Consolidated revenue up 13% to Rs 4,031 cr, PAT up 29% to Rs 574 cr. EPS at Rs 13.51 standalone and Rs 13.74 consolidated. Prior year figures restated for BSV business acquisition done in Nov 2025. Auditor flagged emphasis of matter on income tax proceedings of about Rs 1,909 cr pending appeal. Board approved Rs 150 cr corporate guarantee for BSV subsidiary and Rs 49 cr sale of Broadway Hospitality. Debt-equity improved to 0.25.

Likely market impact

Strong profit growth from operations and BSV contribution. Tax proceedings worth around Rs 1,909 cr remain a watch item for shareholders.